← All trials
NCT05135273
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 22, 2021
- Primary completion
- Jun 30, 2023
- Completion date
- Jun 30, 2023
- First posted
- Nov 26, 2021
- Last posted
- Nov 26, 2021
- Enrollment
- 80
- Arms / groups
- 8 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)Study chair
- NovavaxCollaborator
- Malaria Research and Training Center, Bamako, MaliOverall official - principal investigator
- Malaria Research and Training Center, Bamako, MaliCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.